| abstract |
The present invention relates to (S) -pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5- [2- (2,2,2-trifluoro-1,1-dimethyl-ethyl)]. -Pyridin-4-yl] -thiazol-2-yl} -amide), or pharmaceutically acceptable salts thereof, alpha isoform-specific phosphatidylinositol 3-kinase inhibitor compounds and IGF1R inhibitors (eg, IGF1R A pharmaceutical composition comprising the inhibitor antibody A, or a variant or derivative thereof), a pharmaceutical composition comprising the combination, a method of cancer treatment comprising administering a therapeutically effective amount of the inhibitor to a subject in need thereof; And the use of the combination for cancer treatment. |